Background: Traditional drug payment schemes in Catalonia are generally based on the negotiation of fixed prices; however, disadvantages arise in the case of innovative therapies. Risk sharing agreements distribute potential health and economic uncertainties and high prices on access across the interested parts.Objectives: To identify, characterize and analyze current publicly available agreement reports signed by the Catalan Health Service and different pharmaceutical companies evaluating the current market access scene for new drugs in Catalonia.Methods: A database of agreements implemented between 2013 and 2018 was developed by using publicly available data. Data analysis was performed in a descriptive way, presenting summaries in datasheets.Results: A total of 7 managed entry agreements were analyzed. Two extensions regarding previous agreements were also taken into account. The main involved disease area is oncology (57%) and the most common length is 1 year, whereas the longest is 3 years.Conclusions: Managed entry agreements are gaining popularity and are viewed as positive schemes by stakeholders, payers and health services, leading to a general increase of accords during the last years. However, there are hardly any studies regarding the impact of RSA post-implementation, a field of great relevance regarding health policies.

中文翻译：

---

西班牙加泰罗尼亚地区当前与绩效挂钩和风险分担协议的场景。

背景：加泰罗尼亚的传统药物付款计划通常基于固定价格的谈判；然而，在创新疗法的情况下会产生不利条件。风险分担协议将潜在的健康和经济不确定性以及高昂的价格分布在感兴趣的各个部分。目的：识别，表征和分析由加泰罗尼亚卫生服务局和不同的制药公司签署的当前公开可用的协议报告，评估新市场的当前市场准入情况方法：使用公开数据开发2013年至2018年实施的协议数据库。数据分析以描述性方式进行，在数据表中显示摘要。结果：总共分析了7个管理进入协议。还考虑了有关先前协议的两个扩展。主要涉及的疾病领域是肿瘤学（57％），最常见的病程是1年，最长的病程是3年。结论：受管入境协议越来越受欢迎，被利益相关者，付款人和卫生服务机构视为积极计划，过去几年中协议的普遍增加。但是，几乎没有关于RSA实施后的影响的研究，这是与卫生政策高度相关的领域。导致最近几年协议的普遍增加。但是，几乎没有关于RSA实施后的影响的研究，这是与卫生政策高度相关的领域。导致最近几年协议的普遍增加。但是，几乎没有关于RSA实施后的影响的研究，这是与卫生政策高度相关的领域。